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Given the lethality of H5N1 avian influenza viruses (AIV) and the recurring spread from poultry to humans, an effective vaccine against H5N1
viruses may be needed to prevent a pandemic. We generated experimental vaccine vectors based on recombinant vesicular stomatitis virus (VSV)
expressing the H5 hemagglutinin (HA) from an H5N1 virus isolated in 1997. The HA gene was expressed either from an attenuated wild-type
VSV vector or from a single-cycle vector containing a deletion of the VSV G gene. We found that all of the vectors induced potent neutralizing
antibody titers against the homologous and antigenically heterologous H5N1 viruses isolated in 2004 and 2005. Vaccination of mice with any
combination of prime or prime/boost vectors provided long-lasting protection (N7 months) against challenge with AIV, even in animals receiving a
single dose of single-cycle vaccine. Our data indicate that these recombinants are promising vaccine candidates for pandemic influenza.
© 2007 Elsevier Inc. All rights reserved.Keywords: VSV; AIV; Vaccine; H5N1; Cross neutralizing antibodyIntroduction
The influenza pandemics that occurred in 1918, 1957, and
1968 killed over 40 million people worldwide. Pandemics arise
when novel influenza A subtypes emerge and spread to humans,
generally from avian reservoirs (Wright and Webster, 2001).
Viruses in the influenza A genus are subdivided on the basis of
the antigenicity of the envelope glycoproteins, hemagglutinin
(HA), and neuraminidase (NA). Currently, there are 16 knownAbbreviations: AIV, avian influenza virus; HA, hemagglutinin; HK/156,
AIV strain A/Hong Kong/156/1997; HK/483, AIV strain A/Hong Kong/483/
1997; HPAI, highly pathogenic influenza virus; i.m., intramuscular; i.n.,
intranasal; INA/5, AIV strain A/Indonesia/5/2005; NA, neuraminidase; VSV,
vesicular stomatitis virus; rVSV, recombinant VSV.
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doi:10.1016/j.virol.2007.04.021types of HA (H1–16) and 9 of NA (N1–9) (Fouchier et al.,
2005; Wright and Webster, 2001).
In 1997, outbreaks of the H5N1 subtype of avian influenza
virus (AIV) occurred in Hong Kong, in both poultry and
humans. This was the first time that a H5 subtype was known to
cause disease in humans. H5N1 viruses emerged again in 2003
and continue to cause disease in poultry and humans to the
present day (Gillim-Ross and Subbarao, 2006). Since 2003, at
least 261 people have been infected by H5N1 viruses with an
associated mortality rate of over 60% (http://www.who.int/csr/
disease/avian_influenza). Despite the unusually high mortality
rate, the human outbreaks probably have been contained
because the current H5N1 strains do not spread efficiently
from person to person (Katz et al., 1999; Ungchusak et al.,
2005). This high mortality rate and continued spread triggered
the World Health Organization and the U.S. Centers for Disease
Control and Prevention to issue warnings about a possible
H5N1 pandemic. The H5N1 strains that have emerged since
1997 have already split into numerous sublineages or clades
(2005; Chen et al., 2006), illustrating the rapid evolution of this
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has emphasized the need for vaccines protecting against AIV
infection.
Compared to human influenza vaccines targeting epidemic
influenza, development of AIV vaccines is more problematic.
Traditional influenza vaccines are prepared by growing atte-
nuated reassortant viruses in embryonated chicken eggs. These
attenuated viruses encode the HA and NA proteins predicted to
be present in the upcoming seasonal epidemic viruses.
However, the AIVs with the greatest potential public health
threat are highly pathogenic avian influenza (HPAI) viruses that
can be too pathogenic to grow efficiently in eggs and require
costly levels of biocontainment. Because a newly emerged
H5N1 virus might spread rapidly in the population, the long
lead-time required for traditional vaccine production is also a
major concern.
In an effort to create an H5N1 AIV vaccine, many groups are
exploring new approaches to generate a vaccine that will protect
against H5N1 strains (reviewed in Gillim-Ross and Subbarao,
2006; Horimoto and Kawaoka, 2006). Both inactivated and live
attenuated AIV vaccines are under development. Other
strategies such as inactivated subvirion, recombinant subunit,
and DNAvaccines are being investigated. Virus vectors, such as
adenovirus and Newcastle disease virus vectors, encoding
influenza antigens are also being explored as potential AIV
vaccines for both avian and human use (Ge et al., 2007;
Horimoto and Kawaoka, 2006; Park et al., 2006; Veits et al.,
2006).
Experimental virus vaccine vectors based on attenuated
vesicular stomatitis viruses (VSV) that express foreign viral
antigens have been developed (Brandsma et al., 2007;
Daddario-DiCaprio et al., 2006; Egan et al., 2004; Garbutt et
al., 2004; Jones et al., 2005; Kahn et al., 2001; Kapadia et al.,
2005; Publicover et al., 2005; Ramsburg et al., 2004; Reuter et
al., 2002; Roberts et al., 1998, 1999, 2004; Schlereth et al.,
2000; Schnell et al., 1997). These vectors protect animals
against numerous viral challenges. The initial studies on VSVas
a vaccine vector showed that a VSV expressing the HA protein
of the WSN strain of influenza elicited high neutralizing
antibody titers in mice and protected mice against challenge
with a lethal dose of the WSN virus (Roberts et al., 1998, 1999).
VSV is a versatile vaccine vector for many reasons including
the fact that exposure and seropositivity to VSV is negligible in
the human population. Additionally, it replicates solely in the
cytoplasm, does not undergo recombination, and generates no
DNA intermediates that might integrate into host genomes
(Rose and Whitt, 2001). VSV's relatively simple genome can
accommodate at least 4.5 kb of foreign gene(s) that are highly
expressed in infected cells. Moreover, VSV is effective when
administered intranasally and is easily manufactured on a large
scale in cell lines already approved for vaccine production.
There are also highly attenuated mutants of VSV as well as
replication defective, single-cycle VSV vectors that still gene-
rate potent immune responses (Publicover et al., 2004, 2005;
Roberts et al., 1999).
In the present study, we have generated replicating and
single-cycle VSV vectors that express the H5 HA gene derivedfrom a prototypic H5N1 AIV, A/Hong Kong/156/97 (HK/156),
originally isolated from a lethal human infection (Subbarao
et al., 1998). To assess the efficacy of these vectors, we
examined the ability of the VSVs expressing H5 HA to induce a
neutralizing antibody response against the homologous virus.
Additionally, we determined if these vaccines could elicit cross-
neutralizing antibody titers against distantly related H5N1
viruses. All of our vectors, with and without boosting, were
able to induce a neutralizing antibody response against all H5N1
viruses tested. Furthermore, the response was 100% protective
in a mouse model of AIV challenge. This protection was
achieved with a single dose of vaccine and was long-lasting.
Results
Construction of replication competent and single-cycle VSV
vectors expressing an avian influenza H5 HA protein
In order to generate VSV-based vaccine vectors for H5N1
avian influenza, we incorporated the HA gene from the
H5N1 AIV strain, HK/156, into the three different recom-
binant VSV (rVSV) vectors shown in Fig. 1A. The two
replication competent vectors had the HA gene inserted into
the fifth genome position downstream of the VSV G gene.
One of these vectors (VSV-H5 HA, Fig. 1A) contained the
VSV G from the Indiana serotype. To allow for effective
boosting after priming with the vector containing the Indiana
G protein, the boosting vector substituted this gene with the
VSV G gene from the New Jersey serotype (VSV-NJG-H5
HA, Fig. 1A). Priming with VSV vectors precludes effective
boosting with the same vector because of the high level of
neutralizing antibody generated against the VSV G protein
(Rose et al., 2000). Additionally, we generated a single-cycle
vector where the G gene was deleted (VSVΔG-H5 HA, Fig.
1A). This vector was propagated in a complementing cell
line expressing VSV G (Schnell et al., 1997). However, it
cannot spread in animals beyond initially infected cells
because it does not encode the VSV G protein. Such single-
cycle vectors eliminate concerns about pathogenesis of VSV
recombinants.
Expression of the HA gene from the recombinant VSV vectors
To determine if the H5 HA gene was expressed from these
recombinant vectors, western blot analysis was performed on
whole cell extracts of infected cells. Proteins with the mobi-
lities expected of the H5 HA protein (HA0) and its cleaved
forms (HA1 and HA2) accumulated in cells infected with all
three vectors, but not in cells infected with the parent wild-
type (WT) virus (Fig. 1B, left panel). When the same blot
was stripped and re-probed with anti-VSV (Indiana)
antibodies, VSV proteins were detected in the infected
cells, except for the G protein in cells infected with the
single-cycle vector, VSVΔG-H5 HA, which does not encode
VSV G, or in cells infected with VSV-NJG-H5 HA because
the NJ G protein is not detected well by the anti-VSV
(Indiana) serum (Fig. 1C, left panel). A trace of cross reacti-
Fig. 2. Neutralization of the homologous AIV strain by sera from VSV
vaccinated mice. Mice were vaccinated i.m. or i.n. with VSV-H5 HA (H5;
n=6), VSV-ΔG-H5 HA (ΔG H5; n=6) or the negative control vector, VSV-
Gag (Gag; n=3). At 1 month post-prime, animals were boosted with VSV-
NJG-H5 HA (n=3) where indicated. At various times post-prime, sera from
individual mice were analyzed for a neutralizing antibody response against the
homologous HK/156 AIV strain (3 or 5.5 months post-prime, gray and black
bars, respectively). Each bar represents the neutralizing antibody titer from an
individual mouse as determined by 100% inhibition of CPE in a microneu-
tralization assay.
Fig. 1. Recombinant VSV vectors expressing the H5 HA from the A/HK/156/
97. (A) Diagram of the recombinant VSV vector genomes showing the insertion
site of the H5 HA gene, the replacement of the G gene (Indiana serotype) with
that from the New Jersey (NJ) serotype in the VSV-NJG-H5 HAvector, and the
deletion of the G gene in the VSV-ΔG-H5 HAvector. (B, C) Whole cell extracts
(WCE; left panels) prepared from BHK-21 cells infected with the indicated
viruses or virions purified from infected cell supernatants (right panels) were
subjected to analysis by SDS-PAGE. Western blot analyses were performed
using antibodies specific for (B) H5 HA or (C) VSV. The anti-VSV blot (C) is
the same blot from (B) that was stripped and re-probed with anti-VSV (Indiana)
antibody. The full-length (HA0) and cleaved isoforms (HA1, HA2) of H5 HA as
well as the VSV proteins (G, N, P and M) are indicated by the arrows.
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proteins (Fig. 1C, right panel).
H5 HA is incorporated into the recombinant VSV virions
To determine if the H5 HA protein was incorporated into
recombinant VSV virions, we purified virions by ultracen-
trifugation and then performed a western blot analysis of the
virion proteins with anti-HA antibodies. Fig. 1B (right panel)
shows that the cleaved forms, HA1 and HA2, were incor-
porated into virions of rVSVs expressing HA, but not into WT
virions. The presence of little or no HA0 in the recombinant
virions is expected because HA0 should be cleaved beforereaching the cell surface (Wright and Webster, 2001) where
VSV budding occurs (Rose and Whitt, 2001). Re-probing of
the same blot with anti-VSV serum showed that the expected
VSV proteins were also present in the virions (Fig. 1C, right
panel).
Immunization with the VSV recombinants elicits a potent
neutralizing antibody response to H5N1 AIV
To evaluate the ability of the rVSV vaccine vectors to
generate neutralizing antibodies against avian influenza, mice
were primed intramuscularly (i.m.) or intranasally (i.n.) with
VSV-H5 HA, or i.m only with VSVΔG-H5 HA. Half of the
mice in each group were boosted 1 month later by the respective
route with the G serotype switch vector, VSV-NJG-H5 HA. An
rVSV vector that expresses an unrelated protein was used as a
negative control vector.
Serum antibody responses against the homologous AIV,
HK/156, were analyzed in individual mice at various times
post-prime (Fig. 2) using an AIV microneutralization assay
that measures 100% neutralization of infectivity (Suguitan
et al., 2006). A single dose of either VSV-H5 HA or the
single-cycle vector, VSVΔG-H5 HA, elicited neutralizing
antibody titers against the homologous virus as early as 1 and
2 months post-prime (data not shown), but peaked at 3 months
post-prime (Fig. 2, gray bars). These antibodies persisted at
5.5 months post-prime (Fig. 2, black bars). Neutralizing titers
against HK/156 were enhanced substantially after boosting in
the animals vaccinated i.m. After the prime, the animals
vaccinated i.n. had higher titers than the animals vaccinated
i.m. (Fig. 2). Boosting of the i.n. vaccinees was less effective
(Fig. 2) perhaps because of the presence of a higher initial
level of neutralizing antibodies directed against H5 HA after
the prime.
Fig. 3. Cross-neutralization of heterologous AIV strains by sera from VSV
vaccinated mice. Mice were vaccinated i.m. or i.n. with VSV-H5 HA (H5; n=6),
VSV-ΔG-H5 HA (ΔG H5; n=6), or the negative control vector, VSV-Gag
(Gag; n=3). At 1 month post-prime, animals were boosted with VSV-NJG-H5
HA (n=3) where indicated. At various times post-prime, sera from individual
mice were analyzed for a neutralizing antibody response against the
heterologous strains (A) VN/1203 (gray bars), INA/5 (black bars) (3 months
post-prime), or (B) HK/483 (5.5 months post-prime). Each bar represents the
neutralizing antibody titer from an individual mouse as determined by 100%
inhibition of CPE in a microneutralization assay. The dotted horizontal line at a
value of 10 represents the limit of detect for this assay. A value of 10 is
considered negative. Asterisks (*) indicate mice that were not challenged with
HK/483 (Fig. 4) because they died of unrelated causes (e.g. during anesthesia)
prior to challenge.
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response against heterologous AIV strains
Because of the frequency of antigenic change (drift) in in-
fluenza viruses, it is important to determine if vaccine can-
didates can generate neutralizing antibodies against AIVs fromTable 1
Serologic response to and protection from challenge with HK/483
Antigen a nAb titer b % wt loss c
H5 g 104 (16–640) 2.9 (1.5–6.6)
H5 (Prime only) 54 (16–254) 2.4 (1.6–4.8)
H5 (Prime+Boost) 185 (101–640) 3.4 (1.5–6.6)
Gag 10 (10) 31.6 (25–34.3)
Naive ND 32.4 (30.5–34.5)
a Each row represents the combined data for both i.n. and i.m. routes and for all v
b Summary of individual mouse geometric mean neutralizing antibody (nAb) titer
c Summary of Fig. 4 data as the geometric mean of maximum percent weight (wt
d In parentheses, number of survivors over total number of animals per group.
e When compared to the Gag control group (Logrank test).
f TTD, time to death.
g Sum of rows 2 [H5 (Prime only)] and 3 [H5 (Prime+Boost)].other clades within the same subtype. We therefore examined
the ability of our rVSVs to generate a cross-neutralizing
antibody response against the heterologous AIVs, A/Vietnam/
1203/04 (VN/1203) and A/Indonesia/5/05 (INA/5). These are
viruses from other clades that emerged 7–8 years after isolation
of the HK/156 strain and were isolated in geographically
distinct areas. We found that a single i.m. or i.n. dose of either
VSV-H5 HA or VSVΔG-H5 HA elicited detectable cross-
neutralizing antibodies against the clade 1 virus, VN/1203 (Fig.
3A, gray bars), and the clade 2 virus, INA/5 (Fig. 3A, black
bars) in some of the animals. In general, boosting of the animals
substantially increased the cross-neutralizing antibody titers
against both AIVs (Fig. 3A).
We also examined whether vaccination with these vectors
could induce a cross-neutralizing antibody response against
another more closely related clade 3 virus, A/Hong Kong/483/
97 (HK/483), a HPAI virus. HK/483 is much more pathogenic
in mice than the homologous HK/156 strain (Lu et al., 1999),
and was therefore more suitable for use in the subsequent
challenge studies. A single vaccination elicited substantial
cross-neutralizing antibody titers against HK/483 in individual
mice that were enhanced by boosting (Fig. 3B, Table 1). The
response generated against HK/483 (Fig. 3B) was greater than
that seen against VN/1203 and INA/5 (Fig. 3A), but was lower
than that raised against the homologous clade 3 strain, HK/156
(Fig. 2).
Vaccination confers long-term protection against AIV
challenge
While several experimental vaccine vectors expressing the
H5 HA show promise, to our knowledge no study has examined
the long-term efficacy of vaccination in a mammalian model.
Mice vaccinated with the rVSVs expressing the HK/156 H5 HA
were challenged i.n. with the HPAI HK/483 at 7.5 months post-
prime or 6.5 months post-boost in those animals that were
boosted. The mice that were challenged were the same mice for
which the immunogenicity of the vaccine vectors was
determined (Figs. 2 and 3) except for 5 mice that died prior to
challenge. Mice vaccinated with the negative control virus,
VSV-Gag, lost approximately 30% of their body weight within
the first week post-challenge (Fig. 4) and these mice died by 8–% survival d P-value e TTD (days) f
100 (13/13) b0.0001 NA
100 (6/6) 0.0005 NA
100 (7/7) 0.0002 NA
0 (0/6) NA 8–9
0 (0/2) NA 8
accine vectors expressing the indicated antigen.
s from Fig. 3B, 5.5 months post-prime; range of titers in parentheses.
) loss; percent weight loss range in parentheses.
Fig. 4. Vaccination with VSV vectors expressing a H5 HA protects mice against
a HPAI virus. Balb/c mice were vaccinated (A) i.m. or (B) i.n. with VSV-H5 HA
(squares; n=4 and n=5, respectively), VSVΔG-H5 HA (triangles; n=4), or
VSV-Gag (circles; n=3). At 1 month post-prime, some mice were boosted with
VSV-NJG-H5 HA [solid squares (A, n=2; B, n=3) and solid triangles (A, n=2;
B, n=3)]. At 7.5 months post-prime, mice were challenged i.n. with 100 LD50 of
HK/483. Naive mice (n=2) were also challenged (gray diamonds, dashed line).
For comparison the same group of naive mice is depicted in both panels. Body
weights and survival were assessed daily. *Termination of analysis due to death
of animals.
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Table 1). Mice that were vaccinated with any combination of the
prime and boost vectors, including all mice receiving a single
vaccine dose of either the replicating VSV-H5 HA or the single-
cycle vector, VSVΔG-H5 HA, remained healthy throughout the
duration of the experiment and did not exhibit any weight loss
or other signs of disease (Fig. 4, Table 1). Survival was highly
significant when vaccinated mice were compared to the
VSV-Gag vaccinated control mice with P-values ranging from
b0.0001 to 0.0005 (Table 1). The mean geometric titer against
the challenge virus in these vaccinated animals was 104,
ranging from 16 to 640 (Table 1). Even the animals with the
lowest titers at 5.5 months post-prime (Fig. 3B, Table 1) were
completely protected from challenge at 7.5 months post-prime
(Fig. 4, Table 1). Complete protection was achieved by both i.m.
(Fig. 4A) and i.n. vaccination (Fig. 4B).
Discussion
The highly pathogenic nature of recently emerged H5N1
viruses, the continued spread through poultry populations, and
the high mortality they cause in humans have generated a major
concern about a possible AIV pandemic. This concern has led to
new efforts to develop AIV vaccines including development of
non-traditional methods. VSV vaccine vectors expressing
foreign antigens are capable of providing protection against a
number of respiratory viral diseases, such as SARS (Kapadia et
al., 2005), influenza (Roberts et al., 1998, 1999), and RSV
(Kahn et al., 2001). VSV vectors have shown promise as AIDSvaccines in a monkey model (Egan et al., 2004; Ramsburg et al.,
2004; Rose et al., 2001) and highly attenuated VSVs expressing
HIV antigens will soon be entering clinical trials as experi-
mental AIDS vaccines.
We generated experimental VSV-based H5N1 AIV vaccines
by inserting the H5 HA gene from the HK/156 strain into
recombinant WT and single-cycle VSV vectors. We chose the
H5 HA protein because the only major correlate of protection
against influenza is antibody to its surface glycoproteins, and
primarily to HA (Wright and Webster, 2001). Recovered rVSVs
expressed full-length and cleaved HA in infected cells and the
cleaved HA1 and HA2 were incorporated into the rVSV virions
(Fig. 1). We assessed the serological response to vaccination in
mice after i.n. and i.m. inoculation. Some mice received a single
dose of vaccine while others received a boost with a serotype
switch vector. We found that high neutralizing antibody titers
were present in all mice receiving any combination of the H5-
expressing rVSV vectors by either route. The titers peaked at
about 3 months post-prime, but were still high after 5.5 months
post-prime (Fig. 2).
Because influenza viruses undergo frequent mutation, it is
important that any vaccine intended for pandemic influenza be
able to cross-neutralize antigenically distinguishable AIVs of the
same subtype. We found that our rVSV vectors elicited cross-
neutralizing antibodies against three distinct H5N1 viruses,
VN/1203, INA/5 and HK/483 (Fig. 3, Table 1) at levels
suggestive of protection against these heterologous strains. The
vaccinated mice were challenged at 7.5 months post-prime with
a lethal dose of the HPAI HK/483. All vaccinees, including those
that received a single dose of the single-cycle vector, survived
challenge and were protected from AIV-associated disease
(Fig. 4, Table 1), while all control mice died within 8–9 days
post-challenge.
Our serologic data correlate with complete protection from
pulmonary replication as seen in a previous study after
administration of two doses of a cold-adapted (ca) H5N1
vaccine (Suguitan et al., 2006). The titers induced by the rVSV
vaccines are higher than were achieved after two doses of H5N1
ca vaccine (Suguitan et al., 2006). Moreover, vaccination with
rVSV expressing HA from the WSN strain shows that rVSV
vaccination against influenza can completely prevent influenza
replication in the lungs following challenge (Roberts et al.,
1999). The prevention of AIV-associated weight loss and the
high neutralizing antibody titers after rVSV vaccination in this
study is suggestive of protection against replication. Direct
assay of virus replication was not possible in the BSL-4 facility
where the experiments were carried out and regulations
prevented removal of samples for assay outside of the facility.
Replication will therefore be addressed in future studies.
VSV-based AIV vaccine candidates have potential advan-
tages over other vaccine candidates including ease of delivery
by the intranasal route, negligible VSV seropositivity in
humans, and production in cell lines already approved for
manufacture of human vaccines rather than in eggs. A VSV-
based vaccine also eliminates safety concerns about growing
AIV-based vaccines, such as risk of exposure or accidental
spread during production. Furthermore, VSV vectors are effec-
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here, after a single vaccination not requiring the use of an
adjuvant.
Although WT VSV does not cause neurological disease in
natural host animals, it can be neuroinvasive following
intranasal inoculation of mice (Sabin and Olitsky, 1937). Safety
concerns about use of replication competent VSV vectors have
therefore been addressed. The prototype attenuated VSV vector
(Clarke et al., 2006) is not neuroinvasive in non-human
primates after intranasal administration (Johnson et al., 2006).
Furthermore, more highly attenuated live VSV vectors have
been generated that lack neurovirulence in non-human primates
following direct intracranial (thalamic) inoculation (Johnson et
al., 2006). Also, the vector we described here lacking the VSV
G gene eliminates concerns about neurovirulence because it
replicates for only a single cycle.
Another potential safety concern arises from the fact that the
H5 HA protein is incorporated into VSV virions. However, we
have been unable to demonstrate any infectivity of the viruses
due to the H5 HA protein in the vectors expressing HA.
Because influenza virus requires the receptor-destroying
activity of NA for propagation (Lamb and Krug, 2001), the
absence of the influenza NA gene in our constructs also
predicts lack of pathogenicity due to HA incorporation into
virions. We are currently generating VSV recombinants
expressing soluble, secreted forms of H5 HA that could not
be incorporated into virion membranes. Such recombinants
would provide an additional safety factor, and could potentially
be just as effective at generating neutralizing antibody to
influenza. VSV-based vectors have excellent potential as
vaccines protecting against pandemic AIV and warrant further
development.
Materials and methods
Cells and viruses
BHK-21 and BHK-G (Schnell et al., 1997) cells were grown
in Dulbecco's Modified Essential Medium (DMEM) containing
5% fetal bovine serum (FBS) and 1× Pen-Strep. The BHK-G cell
maintenance media were supplemented with 75 μg/ml G418 and
5 ng/ml tetracycline (Tet). MDCK cells were propagated in
MEM/BSA [minimal essential medium (MEM) supplemented
with 0.3% bovine serum albumin (BSA) and 1× Pen-Strep].
Recombinant VSVs were grown and titrated by plaque assay
on BHK-21 or BHK-G cells as previously described (Lawson et
al., 1995; Schnell et al., 1997). The VSVΔG-H5 HA stock used
for vaccination was resuspended in PBS after centrifugation of
the infected cell media at 25,000 rpm in a Beckman SW28 rotor
(112,398×g) for 1 h at 4 °C. The negative control rVSV vector,
VSV-Gag, containing the SIV Gag gene in the fifth VSV
genome position has been described previously (Rose et al.,
2001).
The AIVs, A/Hong Kong/156/1997 (HK/156), A/Hong
Kong/483/1997 (HK/483), A/Vietnam/1203/2004 (VN/1203),
and A/Indonesia/5/2005 (INA/5), were kindly provided by Drs.
Nancy Cox and Alexander Klimov, Influenza Branch, Centersfor Disease Control and Prevention, Atlanta, GA, and were
propagated in the allantoic cavity of specific pathogen-free eggs
as described previously (Suguitan et al., 2006). HK/483 used for
mouse challenge experiments was grown and titrated by plaque
assay on MDCK cells in media supplemented with 1.0 μg/ml
TPCK-treated trypsin.
Construction and recovery of recombinant VSV vectors
The H5 HA gene (Accession #AF046088; kindly provided
by Y. Kawaoka, University of Wisconsin, Madison, WI) was
amplified by PCR with the primers 5′-GGACCCGGG-
AAAATGGAGAAAACAGTGCTTCTTC-3′ and 5′-GGA-
CTCGAGATCGATCTCTGTTAGTTTTTTCATACCT-
TAAATGCAAATTCTGCATTG-3′ that introduce 5′ XmaI and
3′ XhoI sites (underlined), respectively, and then cloned into
XmaI–XhoI digested pBlueScript II SK to generate pBS-H5.
The H5 HA gene was amplified by PCR from pBS-H5 using the
primers, 5′-GATCGATCCTCGAGATCATGGAGAAAACA-
GTGCTTCTTCTTGC-3′ and 5′-GAAATACTACGCTAGC-
TTAAATGCAAATTCTGCATTGTAAAC-3′ that introduce 5′
XhoI and 3′ NheI sites (underlined), respectively. The XhoI–
NheI digested PCR product was cloned into the XhoI and
NheI sites of the pVSV-XN2 (Schnell et al., 1996) and pVSV-
NJG-XN (Rose et al., 2000) vectors to generate pVSV-H5 HA
and pVSV-NJG-H5 HA, respectively. The pVSVΔG-H5 vector
was generated by replacing the HA gene (A/WSN strain) from
pVSVΔG-HA (Roberts et al., 1999) with the H5 HA PCR
product.
The recombinant VSVs, VSV-H5 HA, and VSV-NJG-H5
HA, were recovered using the above plasmids as previously
described (Lawson et al., 1995). Briefly, BHK-21 cells were
infected with the T7 polymerase expressing vaccinia virus,
vTF7-3 (Fuerst et al., 1986), at aMOI of 10. At 1 h post-infection
(hpi), the cells were transfected with the appropriate H5 HA
plasmids plus the support plasmids, pBS-N, pBS-P, pBS-G, and
pBS-L. The cell culture media was collected, filtered through a
0.2 μm filter, and passaged onto BHK-21 cells 48 h post-
transfection. Once CPE was observed the culture media was
filtered through a 0.1 μm filter, plaque purified, and used to grow
up virus stocks. Growth and recovery of VSVΔG-H5 HAwere
achieved by complementation from BHK-G cells expressing
VSV G (Schnell et al., 1997). In order to optimize titers, either
BHK-G cells or BHK-21 cells transiently expressing G from
pCAGGS-G (Publicover et al., 2005) were used.
Western blot analysis
Cell extracts
BHK-21 cells were infected with the indicated virus. At
4.5 hpi, cells were washed twice with ice-cold PBS and
incubated with lysis buffer (1% NP-40, 0.4% deoxycholate,
62.5 mM EDTA, 50 mM Tris–HCl pH 8) for 5 min on ice.
VSV virions
The culture media of infected cells exhibiting 100% CPE
were clarified by low speed centrifugation, layered on top of
172 J.A. Schwartz et al. / Virology 366 (2007) 166–17320% sucrose in TE (pH 7.4), and subjected to ultracentrifuga-
tion in a Beckman SW50.1 rotor at 38,000 rpm (173,069×g) for
1 h at 4 °C. The pellet was then resuspended in lysis buffer.
SDS-PAGE/Western blot
Infected cell or virion lysates were combined with SDS-
sample buffer [250 mM Tris–HCl pH 6.8, 30% glycerol (v/v),
8% SDS, 0.02% bromophenol blue, 10% 2-mercaptoethanol
(v/v)] and subjected to SDS-PAGE on a 10% acrylamide gel.
The proteins were transferred to nitrocellulose with a semi-dry
transfer apparatus (Bio-Rad Laboratories, Inc., Hercules, CA)
according to the manufacturer's instructions. The blots were
incubated overnight at 4 °C in PBST-milk [PBS containing
0.5% Tween-20 (PBST) and 4% non-fat milk] and then in a
1:1000 dilution of NR-665 polyclonal anti-influenza virus H5
HA A/Hong Kong/156(483)/97 sheep antiserum in PBST-milk
for 1 h at room temperature. The NR-665 antibody was
obtained through the NIH Biodefense and Emerging Infections
Research Repository, NIAID, NIH. After washing 3 times
with PBST, the blots were incubated with donkey anti-sheep
IgG conjugated to HRP (Santa Cruz Biotechnology, Santa
Cruz, CA) at a 1:10,000 dilution in PBST-milk for 1 h. The
blots were washed as before and incubated with a 1:1 mixture
of ECL western blotting detection reagents (GE Healthcare,
Piscataway, NJ). Chemiluminescence was detected using a
LAS-3000 imaging system (Fujifilm). The blots were then
incubated in stripping buffer (62.5 mM Tris–HCl pH 6.8, 2%
SDS, 100 mM 2-mercaptoethanol) for 30 min at 50 °C,
washed several times with PBS, and probed for VSV proteins
as described above using a rabbit polyclonal anti-VSV anti-
body at a 1:1000 dilution and mouse anti-rabbit IgG conju-
gated to HRP (Pierce Biotechnology, Rockford, IL) at a
1:10,000 dilution.
Vaccinations
The Yale University Institutional Animal Care and Use
Committee approved all vaccinations. Six to eight week old
Balb/c female mice (Charles River Laboratories, Wilmington,
MA) were primed i.m. with 50 μl or i.n. with 25 μl containing
106 plaque forming units (pfu) of VSV-H5 HA in DMEM or
approximately 106 pfu of VSVΔG-H5 HA in PBS. Mice
vaccinated i.n. were lightly anesthetized with 20% isoflurane (v/
v; Baxter, Deerfield, IL) in propylene glycol prior to
vaccination. At 1 month post-prime, half of the mice were
boosted i.m. or i.n. with 106 pfu of VSV-NJG-H5 HA in DMEM
as described above.
Microneutralization assay
Anti-H5 HA neutralizing antibody titers were determined as
previously described (Suguitan et al., 2006). Briefly, serum
obtained from vaccinated mice was heat inactivated at 56 °C for
30–60 min and subjected to serial 2-fold dilutions starting at a
1:10 dilution. Equal volumes of 100 TCID50 of the indicated
virus and diluted serum were combined, incubated at room
temperature for 1 h, and added to MDCK cells in quadruplicate.Neutralizing titers are represented as the reciprocal dilution at
100% neutralization as defined by the absence of CPE at 4 days.
Samples that did not display any neutralizing activity were
arbitrarily given a value of 10. These assays were conducted
using enhanced BSL-3 containment procedures in laboratories
approved for use by the U.S. Department of Agriculture and
Centers for Disease Control and Prevention.
H5N1 challenge
At 7.5 months post-prime, vaccinated mice were i.n. chal-
lenged with 100 LD50 (4.5 pfu) of HK/483 in 50 μl MEM/BSA.
The LD50 was determined by the Reed and Muench method
(Reed and Muench, 1938). Mice were weighed daily and
analyzed for disease for 14 days. Mice exhibiting severe
morbidity were humanely euthanized. Data are shown as the
average percent of original pre-challenge weight. The challenge
was performed using BSL-4 containment procedures under an
approved animal use protocol and according to the guidelines of
the Canadian Council on Animal Care.
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